Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (31-40 of 124) with videos related to

Pageof 13
Sort By:
Neuroimage. Clinical|November 22, 2017
Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry studyNiels Bergsland, Dana Horakova, Michael G Dwyer, et al.
The Lancet. Neurology|April 13, 2012
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyVirginia Devonshire, Eva Havrdova, Ernst Wilhelm Radue, et al.
Neuroimage. Clinical|November 8, 2014
MRI correlates of disability progression in patients with CIS over 48 monthsTomas Uher, Dana Horakova, Niels Bergsland, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2017
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE studyLudwig Kappos, Eva Havrdova, Gavin Giovannoni, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|May 3, 2017
A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative StudyTomas Uher, Jan Krasensky, Manuela Vaneckova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 8, 2016
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosisTomas Uher, Manuela Vaneckova, Lukas Sobisek, et al.
Clinical Therapeutics|November 4, 2015
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III StudiesGavin Giovannoni, Ralf Gold, Robert J Fox, et al.
Current Medical Research and Opinion|November 8, 2013
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparisonMichael Hutchinson, Robert J Fox, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2012
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabPer Soelberg Sørensen, Antonio Bertolotto, Gilles Edan, et al.
Journal of the Neurological Sciences|January 27, 2009
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal studyDana Horakova, Michael G Dwyer, Eva Havrdova, et al.
Pageof 13

Showing results (31-40 of 124) with videos related to

Sort By:
Pageof 13
Neuroimage. Clinical|November 22, 2017
Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry studyNiels Bergsland, Dana Horakova, Michael G Dwyer, et al.
The Lancet. Neurology|April 13, 2012
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyVirginia Devonshire, Eva Havrdova, Ernst Wilhelm Radue, et al.
Neuroimage. Clinical|November 8, 2014
MRI correlates of disability progression in patients with CIS over 48 monthsTomas Uher, Dana Horakova, Niels Bergsland, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2017
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE studyLudwig Kappos, Eva Havrdova, Gavin Giovannoni, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|May 3, 2017
A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative StudyTomas Uher, Jan Krasensky, Manuela Vaneckova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 8, 2016
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosisTomas Uher, Manuela Vaneckova, Lukas Sobisek, et al.
Clinical Therapeutics|November 4, 2015
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III StudiesGavin Giovannoni, Ralf Gold, Robert J Fox, et al.
Current Medical Research and Opinion|November 8, 2013
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparisonMichael Hutchinson, Robert J Fox, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2012
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabPer Soelberg Sørensen, Antonio Bertolotto, Gilles Edan, et al.
Journal of the Neurological Sciences|January 27, 2009
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal studyDana Horakova, Michael G Dwyer, Eva Havrdova, et al.
Pageof 13